Etanercept: Effectiveness and safety data of a retrospective study

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 9, 2011, Pages 1113-1115

  Antoniou, C ^a   Vergou, T ^a   Dessinioti, C ^a   Stratigos, A J ^a   Avgerinou, G ^a   Stavropoulos, P ^a   Katsambas, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; AMINOTRANSFERASE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; METHOTREXATE; PSORALEN;

ADD ON THERAPY; ADULT; AGED; BRAIN HEMANGIOMA; BREAST CANCER; BRONCHITIS; CONDYLOMA ACUMINATUM; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GENERALIZED EDEMA; HAIR LOSS; HERPES SIMPLEX; HUMAN; INJECTION SITE REACTION; LEG THROMBOSIS; LETTER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PSORIASIS; PUVA; RETROSPECTIVE STUDY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SYNCOPE; THROMBOSIS; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; WALKING DIFFICULTY; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 80051677682     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03820.x     Document Type: Letter

References (7)

1. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G,. Weight loss improves the response of obese patients with moderate-to severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88 (5): 1242-1247.
2. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726. (Pubitemid 46955730)
3. Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F,. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 2007; 17 (6): 546-547. (Pubitemid 350207176)
4. Driessen RJB, Boezeman JB, Van de Kerkhof PCM, De Jong EM,. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675.
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022. (Pubitemid 37448924)
6. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312. (Pubitemid 40933433)
7. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue and depression in psoriasis: double-blind placebo controlled randomized phase III trial. Lancet 2006; 367: 29-35. (Pubitemid 43038667)